Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain.
Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain; Universitat de Barcelona (UB), Barcelona 08028, Spain.
Mol Ther. 2021 Feb 3;29(2):804-821. doi: 10.1016/j.ymthe.2020.10.026. Epub 2020 Dec 1.
Cell therapy approaches hold great potential for treating retinopathies, which are currently incurable. This study addresses the problem of inadequate migration and integration of transplanted cells into the host retina. To this end, we have identified the chemokines that were most upregulated during retinal degeneration and that could chemoattract mesenchymal stem cells (MSCs). The results were observed using a pharmacological model of ganglion/amacrine cell degeneration and a genetic model of retinitis pigmentosa, from both mice and human retinae. Remarkably, MSCs overexpressing Ccr5 and Cxcr6, which are receptors bound by a subset of the identified chemokines, displayed improved migration after transplantation in the degenerating retina. They also led to enhanced rescue of cell death and to preservation of electrophysiological function. Overall, we show that chemokines released from the degenerating retinae can drive migration of transplanted stem cells, and that overexpression of chemokine receptors can improve cell therapy-based regenerative approaches.
细胞疗法在治疗目前无法治愈的视网膜病变方面具有巨大的潜力。本研究解决了移植细胞向宿主视网膜迁移和整合不足的问题。为此,我们鉴定了在视网膜变性过程中上调最明显的趋化因子,这些趋化因子可以趋化间充质干细胞(MSCs)。结果在神经节/无长突细胞变性的药理学模型和色素性视网膜炎的遗传模型中,从老鼠和人视网膜中观察到。值得注意的是,过表达 Ccr5 和 Cxcr6 的 MSCs 是由一组鉴定出的趋化因子结合的受体,在变性视网膜中移植后表现出改善的迁移。它们还导致细胞死亡的挽救增强,并保留电生理功能。总的来说,我们表明从变性视网膜中释放的趋化因子可以驱动移植干细胞的迁移,并且过表达趋化因子受体可以改善基于细胞疗法的再生方法。